Washington, DC (May 23, 2018) – Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc., provided testimony today on behalf of the Biotechnology Innovation Organization (BIO) before the House of Representatives Committee on Financial Services, Subcommittee on Capital Markets, Securities, and Investment. Hahn serves as the Co-Chair of BIO’s Finance & Tax Committee.

Washington, D.C. (May 23, 2018) - Even with the abundance of high-profile international companies that will converge in Boston for the 2018 BIO International Convention, it’s difficult to overstate the work that is being done in Boston’s backyard. The New England region is one of the top life sciences clusters in the world, with Boston being home to many bioscience companies. 

Aactor, director and advocate Rob Reiner will deliver a keynote address at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7. Reiner’s family story of drug addiction reinforces the urgent need for biotechnology innovation in pain management

Washington, D.C. (May 16, 2018) – Trace Sheehan, writer and producer of the highly-acclaimed documentary film Food Evolution, will be a keynote speaker at BIO’s International Convention in Boston, the Biotechnology Innovation Organization (BIO) announced today.

“We have concerns that some of the ideas proposed today could, if adopted, hurt patient access to the medicines they need …”

Washington, D.C. (May 9, 2018) – Biotechnology Innovation Organization President for Advocacy, Law & Public Policy Tom DiLenge today issued the following statement in response to the U.S. Patent and Trademark Office’s (PTO) proposed change to claim construction standards used by the Patent Trial and Appeal Board (PTAB):“BIO applauds Director Iancu and the PTO for proposing regulations that would change how the office interprets claims in administrative patent challenge proceedings.“BIO has long advocated for this particular rule change, and for more balance and fairness in the Inter Partes Review (IPR) system generally.  This rule brings us closer to that reality, and we urge the Director to continue down this path with additional changes to improve the system further.“Under the agency’s current proposal, IPRs and related post-issuance proceedings would use the same claim interpretation standard that is being used by federal courts in patent litigation. This approach will improve predictability in the post-issuance review process and help mitigate against inconsistent results that can occur when the same patent is adjudicated in different fora.“BIO urges the PTO to quickly finalize this rule to strengthen intellectual property protections and improve the ability of patent owners to defend their inventions and businesses against infringement.”About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations…

BIO thanked President Trump and Senators Charles Grassley (R-IA) and Joni Ernst (R-IA) for rejecting a price cap on Renewable Identification Numbers (RINs) and working to provide regulatory relief to enable year-round sales of E15.